Age: 0.57
Sex: M
Vaccine: DTAP, HEP
Symptoms: Psychomotor hyperactivity, Sensory disturbance, Speech disorder, Upper respiratory tract infection
Clinical narrative: This case was reported by a lawyer and described the occurrence of nerve damage in a male subject of unspecified age who was vaccianted with hepatitis B vaccine (Engerix B, hepatitis B vaccine, DTaP, Oral polio, MMR and Varicella. A physician or other health care professional has not verified this report. On 1/13/97 and 8/29/96 the subject received 3rd and 3nd dose of Engerix B (unk), on 6/21/96 the subject received 1st dose of Hep B (unk). On 8/15/00 the subject received 5th dose of Dtap (unk). On 8/15/00 and 1/13/96 the subject received 4th dose and 3rd dose of OPV. On 8/15/00 the subject received 2nd dose of MMR vaccine (unk), 1st dose of Varicella vaccine (unk). At an unspecified time after vaccination with DPTa, Engerix B, Hep B, MMR, OPV, and Varicella, the subject experienced nerve damage, toxic effect of mercury and its compounds, communication disorder, pervasive developmental disorder, attention deficit, impulsivity, motor deficiency, aspergers syndrome, violent outburst, aggression, sensitivity and delayed speech. According to the legal complaint at an unspecified time after vaccination with hepatitis B vaccine, the subject experienced neurological damage, which was attributed to cumulative mercury toxicity. The following information was received via medical records. Mother was a 30 year old gravida 2 par 1 to 2. Delivery at 38 weeks and 6 days of gestation. Pregnancy consisted of uncomplicated labor and delivery with a term spontaneous vaginal delivery. Apgar was unk. No significant complications during the pregnancy. No alcohol or tobacco used. Infant weighed 8 lbs and 6.2 oz. 3/600 an audiology evaluation was normal. On 11/17/00 subject was 4 years old and was evaluated for significant social delay, atypical language development. Past medical history was unremarkable except for rare otitis medical and upper respiratory infection. Symptoms include difficulty with transitions, some perseveration, mouthing of objects and some anxiety. The physical examination revealed that his language appeared younger than expected for his age. His extremities are without gross joint deformity except for mild bilateral clindactyly of the 5th digit on each hand. Cranial nerve II through XII are grossly intact. Cogniti9ve screening revealed that the subject was less than the 3 year 6 month level. The physician concluded that the subject does not meet the criteria for infantile autism. He appears to have a communication disorder and may fall within in the mild pervasive developmental disorder. It was believed that there is a familial etiology. There is no evidence to suggest neither childhood disintegrative disorder nor a neurodegenerative proves. History of pica, attention deficits as well as some impulsivity were noted. He was diagnosed with communication disorder probable mild pervasive developmental disorder non specified and minor neuromotor abnormalities including visual motor delay. Lead testing on 11/30/00 was 4 mcg/dl (less than 9mcg/dl not considered indicative of lead poisoning). On 6/19/02 the 6 year old subject was evaluated by a neurodevelopmental pediatric program. Developmental history included walking independently at 1 year. Speaking in single words at about 9 months and speaking in 2 word sentences between 2 and 2? years. Articulation was problematic for the first year. Family history was significant for a paternal uncle who has social anxiety but no other family members with known developmental disorders. The physician agreed with the previous diagnosis of pervasive developmental delay. It was noted that he also experienced ADD including over activity and a short attention span. 6/16/03 he was evaluated for increased aggression, to include pinching himself, head banging and biting his teacher. Report that he was very sensitive to sound, touch and taste. Diagnoses noted were pervasive developmental disorder and Aspergers syndrome. Treatment with Risperidol and Neurontin. Last evaluated on 12/15/03 and the event were unresolved. This case was assessed as medically serious by manufacturer (OMIC). At the time of reporting the outcome of the events were was unspecified.